Abstract
CUDC-907 is a novel dual-acting inhibitor of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC). In this study, we aimed to explore the anticancer effects of CUDC-907 on human breast cancer cells. Our results showed that CUDC-907 effectively inhibited breast cancer cell proliferation. Flow cytometry analysis revealed that CUDC-907 induced cell cycle arrest and apoptosis in breast cancer cells. The combined treatment of CUDC-907 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resulted in a marked increase in apoptosis and cleavage of caspase-8, −9 and poly (ADP-ribose) polymerase (PARP) in breast cancer cells. CUDC-907 enhanced expressions of death receptor 5 (DR5), reduced the levels of anti-apoptotic molecules XIAP, Bcl-2 and Bcl-xL. Knockdown of DR5 abrogated apoptosis induced by the combination of CUDC-907 and TRAIL in breast cancer cells. CUDC-907 increased the phosphorylation of JNK and p38 MAPK. JNK inhibitor pretreatment attenuated CUDC-907-induced upregulation of DR5. In summary, CUDC-907 shows potent cytotoxicity against breast cancer cells and facilitates TRAIL-mediated apoptosis through DR5 upregulation. The combination of CUDC-907 and TRAIL may be a promising therapeutic approach in the treatment of breast cancer.
Similar content being viewed by others
References
Abdulghani J, El-Deiry WS (2010) TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 14:1091–1108. https://doi.org/10.1517/14728222.2010.519701
Carlsten M, Namazi A, Reger R, Levy E, Berg M, St Hilaire C, Childs RW (2018) Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5. Oncoimmunology 8:e1534664. https://doi.org/10.1080/2162402X.2018.1534664
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. C A Cancer J Clin 66:115–132. https://doi.org/10.3322/caac.21338
Chen Y, Peubez C, Smith V, Xiong S, Kocsis-Fodor G, Kennedy B, Wagner S, Balotis C, Jayne S, Dyer MJS, Macip S (2019) CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL. J Cell Mol Med 23:340–348. https://doi.org/10.1111/jcmm.13935
Das S, Tripathi N, Siddharth S, Nayak A, Nayak D, Sethy C, Bharatam PV, Kundu CN (2017) Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis. Apoptosis 22:1205–1224. https://doi.org/10.1007/s10495-017-1400-4
Jang JY, Kang YJ, Sung B, Kim MJ, Park C, Kang D, Moon HR, Chung HY, Kim ND (2018) MHY440, a novel topoisomerase Ι inhibitor, induces cell cycle arrest and apoptosis via a ROS-dependent DNA damage signaling pathway in AGS human gastric cancer cells. Molecules 24:96. https://doi.org/10.3390/molecules24010096
Kotian S, Zhang L, Boufraqech M, Gaskins K, Gara SK, Quezado M, Nilubol N, Kebebew E (2017) Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases. Clin Cancer Res 23:5044–5054. https://doi.org/10.1158/1078-0432.CCR-17-1043
Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS (2015) Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets 19:1171–1185. https://doi.org/10.1517/14728222.2015.1049838
Li M, Wang Y, Wei F, An X, Zhang N, Cao S, Ren B, Zhang X, Ren X (2018) Efficiency of cytokine-induced killer cells in combination with chemotherapy for triple-negative breast cancer. J Breast Cancer 21:150–157. https://doi.org/10.4048/jbc.2018.21.2.150
Liu PC, Lu G, Deng Y, Wang CD, Su XW, Zhou JY, Chan TM, Hu X, Poon WS (2017) Inhibition of NF-κB pathway and modulation of MAPK signaling pathways in glioblastoma and implications for lovastatin and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) combination therapy. PLoS One 12:e0171157. https://doi.org/10.1371/journal.pone.0171157
Li X, Su Y, Madlambayan G, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Ma J, Knight T, Wang G, Wang Y, Yang J, Taub JW, Lin H, Ge Y (2019) Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia. Haematologica 104:2225–2240. https://doi.org/10.3324/haematol.2018.201343
Li Y, Seto E (2016) HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med 6. https://doi.org/10.1101/cshperspect.a026831
McKenna M, McGarrigle S, Pidgeon GP (2018) The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. Biochim Biophys Acta Rev Cancer 1870:185–197. https://doi.org/10.1016/j.bbcan.2018.08.001
McRee AJ, Marcom PK, Moore DT, Zamboni WC, Kornblum ZA, Hu Z, Phipps R, Anders CK, Reeder-Hayes K, Carey LA, Weck KE, Perou CM, Dees EC (2018) A phase I trial of the PI3K inhibitor buparlisib combined with capecitabine in patients with metastatic breast cancer. Clin Breast Cancer 18:289–297. https://doi.org/10.1016/j.clbc.2017.10.014
Nahleh Z, Botrus G, Dwivedi A, Jennings M, Nagy S, Tfayli A (2019) Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: a meta-analysis of randomized controlled trials. Mol Clin Oncol 10:357–365. https://doi.org/10.3892/mco.2019.1796
Pal S, Kozono D, Yang X, Fendler W, Fitts W, Ni J, Alberta JA, Zhao J, Liu KX, Bian J, Truffaux N, Weiss WA, Resnick AC, Bandopadhayay P, Ligon KL, DuBois SG, Mueller S, Chowdhury D, Haas-Kogan DA (2018) Dual HDAC and PI3K inhibition abrogates NFκB- and FOXM1-mediated DNA damage response to Radiosensitize pediatric high-grade Gliomas. Cancer Res 78:4007–4021. https://doi.org/10.1158/0008-5472.CAN-17-3691
Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M, Zifcak B, Ma AW, DellaRocca S, Borek M, Zhai HX, Cai X, Voi M (2012) Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res 18:4104–4113. https://doi.org/10.1158/1078-0432.CCR-12-0055
Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C, Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva AP, Hackl W, Quadt C, Demanse D, Duval V, Baselga J (2018) Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemother Pharmacol 82:285–298. https://doi.org/10.1007/s00280-018-3610-z
Scimeca M, Urbano N, Bonfiglio R, Duggento A, Toschi N, Schillaci O, Bonanno E (2019) Novel insights into breast cancer progression and metastasis: a multidisciplinary opportunity to transition from biology to clinical oncology. Biochim Biophys Acta Rev Cancer 1872(1):138–148. https://doi.org/10.1016/j.bbcan.2019.07.002
Selvarajoo K (2017) A systems biology approach to overcome TRAIL resistance in cancer treatment. Prog Biophys Mol Biol 128:142–154. https://doi.org/10.1016/j.pbiomolbio.2017.02.009
Shlyakhtina Y, Pavet V, Gronemeyer H (2017) Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells. Cell Death Dis 8:e3025. https://doi.org/10.1038/cddis.2017.423
Singh BN, Zhou H, Li J, Tipton T, Wang B, Shao G, Gilbert EN, Li Q, Jiang SW (2011) Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol 7:1415–1428. https://doi.org/10.2217/fon.11.124
Sun K, Atoyan R, Borek MA, Dellarocca S, Samson ME, Ma AW, Xu GX, Patterson T, Tuck DP, Viner JL, Fattaey A, Wang J (2017) Dual HDAC and PI3K inhibitor CUDC-907 downregulates MYC and suppresses growth of MYC-dependent cancers. Mol Cancer Ther 16:285–299. https://doi.org/10.1158/1535-7163.MCT-16-0390
Vancurova I, Uddin MM, Zou Y, Vancura A (2018) Combination therapies targeting HDAC and IKK in solid tumors. Trends Pharmacol Sci 39:295–306. https://doi.org/10.1016/j.tips.2017.11.008
von Karstedt S, Montinaro A, Walczak H (2017) Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer 17:352–366. https://doi.org/10.1038/nrc.2017.28
Wang J, Chang L, Lai X, Li X, Wang Z, Huang Z, Huang J, Zhang G (2018) Tetrandrine enhances radiosensitivity through the CDC25C/CDK1/cyclin B1 pathway in nasopharyngeal carcinoma cells. Cell Cycle 17:671–680. https://doi.org/10.1080/15384101.2017.1415679
Weinberg MA (2016) RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes. Anti-Cancer Drugs 27:475–487. https://doi.org/10.1097/CAD.0000000000000354
Wu W, Yang Y, Deng G, Ma L, Wei G, Zheng G, Han X, He D, Zhao Y, He J, Cai Z, Yu R (2017) Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells. Mol Carcinog 56:2190–2199. https://doi.org/10.1002/mc.22672
Yuan X, Gajan A, Chu Q, Xiong H, Wu K, Wu GS (2018) Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev 37:733–748. https://doi.org/10.1007/s10555-018-9728-y
Yuan Z, Rezai-Zadeh N, Zhang X, Seto E (2009) Histone deacetylase activity assay. Methods Mol Biol 523:279–293. https://doi.org/10.1007/978-1-4939-2474-5_7
Zheng J, Zhang M, Zhang L, Ding X, Li W, Lu S (2018) HSPC159 promotes proliferation and metastasis by inducing epithelial-mesenchymal transition and activating the PI3K/Akt pathway in breast cancer. Cancer Sci 109:2153–2163. https://doi.org/10.1111/cas.13631
Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (No 81703039; No 81570158); Shandong Provincial Natural Science Foundation, China (No ZR2018MH026).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Li, ZJ., Hou, YJ., Hao, GP. et al. CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells. J. Cell Commun. Signal. 14, 377–387 (2020). https://doi.org/10.1007/s12079-020-00558-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12079-020-00558-3